BioSpace6d
PTC Scraps ALS Asset Utreloxastat After Mid-Stage Fail, Analysts Look to PKU Opportunity
Despite the “unfortunate” failure, William Blair analysts do not believe that the utreloxastat readout will heavily affect ...
FierceBiotech6d
PTC axes utreloxastat program after phase 2 ALS failure
But utreloxastat had little effect on ALS in the phase 2 trial. PTC powered the study to show whether twice-daily oral dosing ...
PTC's utreloxastat fails Phase 2 clinical study for ALS
PTC Therapeutics (NASDAQ:PTCT) said a Phase 2 placebo-controlled study of its ALS drug candidate utreloxastat failed to meet ...
Morningstar7d
PTC Therapeutics Announces Topline Results of CardinALS Trial of Utreloxastat in ALS Patients
Utreloxastat was demonstrated to be safe and well tolerated in the CardinALS trial. However, due to the lack of efficacy and biomarker signal, further development is not planned at this time. PTC ...
FierceBiotech6d
PTC sells priority review voucher from Kebilidi approval for $150M
PTC Therapeutics may reeling from the failure of its amyotrophic lateral sclerosis (ALS) drug utreloxastat yesterday, but the ...
PTC Therapeutics: ALS Drug Fail Kicks Off Critical Year Of Catalysts
PTC Therapeutics faces significant risks with its key revenue sources, Translarna and Emflaza. Find out why I am sticking ...
PTC Therapeutics: Phase 2 CardinALS study did not meet its primary endpoint
PTC Therapeutics (PTCT) announced that the global Phase 2 placebo-controlled CardinALS study did not meet its primary endpoint of slowing ...